- Molecular NameErgotamine
- SynonymNA
- Weight581.673
- Drugbank_IDDB00696
- ACS_NO113-15-5
- Show 2D model
- LogP (experiment)2.53
- LogP (predicted, AB/LogP v2.0)1.4
- pka6.4
- LogD (pH=7, predicted)1.23
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.94
- LogSw (predicted, AB/LogsW2.0)15.43
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors3
- No.of HBond Acceptors10
- No.of Rotatable Bonds4
- TPSA118.21
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn ergopeptine and part of the ergot family of alkaloids; it is structurally and biochemically closely related to ergoline. It possesses structural similarity to several neurotransmitters, and has biological activity as a vasoconstrictor. It is used medicinally for treatment of acute migraine attacks (sometimes in combination with caffeine), and to induce childbirth and prevent post-partum haemorrhage.
- Absorption_value100.0
- Absorption (description)Poorly absorbed after oral administration; the extent and rate of absorption is increased if caffeine is administered concurrently.
- Caco_2N/A
- Bioavailability2.0
- Protein bindingN/A
- Volume of distribution (VD)2 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmErgotamine is rapidly metabolised in the liver
- Half life2 h
- ExcretionExcreted mainly in the bile as metabolites; only traces of unchanged drug are excreted in the urine or faeces.
- Urinary ExcretionN/A
- Clerance11 ml/min/kg
- ToxicityErgotamine is highly toxic; in large repeated doses it can produce all the symptoms of ergot poisoning. Fatal poisoning has occurred after the oral administration of 26 mg of ergotamine over a period of several days, and also following single injections of only 0.5 to 1.5 mg.
- LD50 (rat)N/A
- LD50 (mouse)N/A